Becton, Dickinson and Company (NYSE:BDX) insider Nabil Shabshab sold 6,149 shares of the stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total value of $1,240,622.24. Following the sale, the insider now owns 15,648 shares of the company’s stock, valued at approximately $3,157,140.48. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Becton, Dickinson and Company (NYSE:BDX) traded down 0.26% during trading on Wednesday, hitting $200.96. The company had a trading volume of 496,084 shares. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The firm’s 50 day moving average is $199.29 and its 200-day moving average is $188.36. The stock has a market capitalization of $45.73 billion, a price-to-earnings ratio of 58.20 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the previous year, the company earned $2.35 earnings per share. Becton, Dickinson and’s quarterly revenue was down 5.1% compared to the same quarter last year. On average, equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.45%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

WARNING: “Insider Selling: Becton, Dickinson and Company (BDX) Insider Sells 6,149 Shares of Stock” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/insider-selling-becton-dickinson-and-company-bdx-insider-sells-6149-shares-of-stock.html.

Large investors have recently made changes to their positions in the stock. Integrated Wealth Management boosted its stake in shares of Becton, Dickinson and by 3.4% in the first quarter. Integrated Wealth Management now owns 5,444 shares of the medical instruments supplier’s stock worth $999,000 after buying an additional 181 shares during the period. Starfire Investment Advisers Inc. bought a new stake in shares of Becton, Dickinson and during the first quarter worth $409,000. Cribstone Capital Management LLC boosted its stake in shares of Becton, Dickinson and by 320.2% in the first quarter. Cribstone Capital Management LLC now owns 874 shares of the medical instruments supplier’s stock worth $161,000 after buying an additional 666 shares during the period. Doyle Wealth Management bought a new stake in shares of Becton, Dickinson and during the first quarter worth $434,000. Finally, Pinnacle Bank bought a new stake in shares of Becton, Dickinson and during the first quarter worth $192,000. 75.57% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently commented on BDX shares. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $186.00 to $200.00 in a report on Monday, April 24th. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. Cowen and Company reiterated an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Finally, BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $195.79.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Insider Buying and Selling by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.